NCT01430585 - Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Early Breast Cancer (Phase 2)Advanced Breast Cancer (Phase 1b)

Interventions

DRUG

PF-04691502

PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.

DRUG

PF-04691502 in combination with Letrozole

PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.

DRUG

Letrozole

Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.

Trial Locations (5)

6000

Pfizer Investigational Site, Charleroi

20132

Pfizer Investigational Site, Milan

08035

Pfizer Investigational Site, Barcelona

413 45

Pfizer Investigational Site, Gothenburg

171 76

Pfizer Investigational Site, Stockholm